1359657-45-6
Chemical Structure
Vasculotide
- CAS No.: 1359657-45-6
- Formula:N/A
- Molecular Weight:14000 (average)
SMILES: O=C(CCN1C(CC(SC[C@@H](C(N[C@@H](CC2=CN=CN2)C(N[C@H](CC3=CN=CN3)C(N[C@@H](CC4=CN=CN4)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC5=CN=CN5)C(N[C@H](CO)C(N[C@H](C(O)=O)CC6=CC=CC=C6)=O)=O)=O)=O)=O)=O)=O)N)C1=O)=O)NCCOCCOCC(COCCOCCNC(CCN7C(C(SC[C@@H](C(N[C@@H](CC8=CN=CN8)C(N[C@H](CC9=CN=CN9)C(N[C@@H](CC%10=CN=CN%10)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%11=CN=CN%11)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%12=CC=CC=C%12)=O)=O)=O)=O)=O)=O)=O)N)CC7=O)=O)=O)(COCCOCCNC(CCN%13C(C(SC[C@H](N)C(N[C@@H](CC%14=CN=CN%14)C(N[C@H](CC%15=CN=CN%15)C(N[C@@H](CC%16=CN=CN%16)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%17=CN=CN%17)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%18=CC=CC=C%18)=O)=O)=O)=O)=O)=O)=O)CC%13=O)=O)=O)COCCOCCNC(CCN%19C(C(SC[C@H](N)C(N[C@@H](CC%20=CN=CN%20)C(N[C@H](CC%21=CN=CN%21)C(N[C@@H](CC%22=CN=CN%22)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC%23=CN=CN%23)C(N[C@H](CO)C(N[C@H](C(O)=O)CC%24=CC=CC=C%24)=O)=O)=O)=O)=O)=O)=O)CC%19=O)=O)=O.[n].[n].[n].[n]
Biological Activity: Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vasculotide | 99.84% | Vasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Dekker NAM, et al. Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. Br J Anaesth. 2018;121(5):1041-1051. [Content Brief]
- [2]. Korpela E, et al. Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model. BMC Cancer. 2014;14:614. Published 2014 Aug 26. [Content Brief]
- [3]. Lynch M, et al. Vasculotide restores the blood-brain barrier after focused ultrasound-induced permeability in a mouse model of Alzheimer's disease. Int J Med Sci. 2021;18(2):482-493. Published 2021 Jan 1. [Content Brief]
- [4]. Lask A, et al. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice. Sci Rep. 2022;12(1):15531. Published 2022 Sep 15. [Content Brief]
Keywords
